Healthcare Wrap: Cann Group, OncoSil and Imugene Power a Big Week

• Cann Group jumped 50% after moving to redeem convertible notes and expand its credit facility.
• OncoSil surged 45.93% as its US device application entered final FDA review and a European trial deal cut study costs.
• Imugene climbed 39.18% after two complete responses in hard-to-treat lymphoma patients.
• Neuren, Saluda and Neurotech also posted strong gains on regulatory and patent news.